Literature DB >> 2832208

Effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxycarbonylme tho xy coumarin) on cyclic nucleotide phosphodiesterases in human platelets.

G Hakim1, D Fiorentini, A Falasca, M Prosdocimi, C A Rossi.   

Abstract

The effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxycarbonylmeth oxy coumarin), an inhibitor of platelet aggregation, on cyclic nucleotide metabolism was investigated. AD6 inhibited selectively human platelet cyclic GMP phosphodiesterase, which was separated from cyclic AMP phosphodiesterase by DEAE-cellulose chromatography. Addition of AD6 to washed platelets increased cyclic GMP levels significantly in two minutes. These results could be useful in elucidating the action of AD6 on intact platelets.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2832208     DOI： 10.1007/BF01941715

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  13 in total

Review 1.  Regulation of blood platelet function by cyclic nucleotides.

Authors:  R J Haslam; M M Davidson; T Davies; J A Lynham; M D McClenaghan
Journal:  Adv Cyclic Nucleotide Res       Date:  1978

2.  AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxycarbonyl-meth oxy coumarin) inhibits the release of arachidonic acid in human platelets stimulated by thrombin.

Authors:  S Porcellati; V Costantini; M Prosdocimi; R Pistolesi; P Porrovecchio; G G Nenci; G Goracci
Journal:  Thromb Res       Date:  1987-07-01       Impact factor: 3.944

3.  Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents.

Authors:  R E Weishaar; S D Burrows; D C Kobylarz; M M Quade; D B Evans
Journal:  Biochem Pharmacol       Date:  1986-03-01       Impact factor: 5.858

4.  Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase--basic and potential clinical applications.

Authors:  H Hidaka; T Endo
Journal:  Adv Cyclic Nucleotide Protein Phosphorylation Res       Date:  1984

5.  Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.

Authors:  M Hagiwara; T Endo; T Kanayama; H Hidaka
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

6.  Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase.

Authors:  H Hidaka; T Asano
Journal:  Biochim Biophys Acta       Date:  1976-04-08

7.  Inhibitory action of cyclic GMP on secretion, polyphosphoinositide hydrolysis and calcium mobilization in thrombin-stimulated human platelets.

Authors:  S Nakashima; T Tohmatsu; H Hattori; Y Okano; Y Nozawa
Journal:  Biochem Biophys Res Commun       Date:  1986-03-28       Impact factor: 3.575

8.  Mepacrine-induced inhibition of human platelet cyclic-GMP phosphodiesterase.

Authors:  T Yamakado; F Tanaka; H Hidaka
Journal:  Biochim Biophys Acta       Date:  1984-09-07

9.  7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.

Authors:  R Muggli; T B Tschopp; E Mittelholzer; H R Baumgartner
Journal:  J Pharmacol Exp Ther       Date:  1985-10       Impact factor: 4.030

10.  The effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7-ethoxy- carbonylmethoxycoumarin) on washed human platelet aggregation induced by platelet activating factor (PAF) and epinephrine.

Authors:  A Zanetti; A Zatta; M Prosdocimi; E Dejana
Journal:  Eur J Pharmacol       Date:  1986-08-22       Impact factor: 4.432
View more
  6 in total

1.  Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats.

Authors:  S Cuzzocrea; E Mazzon; C Bevilaqua; G Costantino; D Britti; G Mazzullo; A De Sarro; A P Caputi
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  The coumarin derivative AD6 inhibits the release of arachidonic acid by interfering with phospholipase A2 activity in human platelets stimulated with thrombin.

Authors:  S Porcellati; V Costantini; M Prosdocimi; M Stasi; R Pistolesi; G G Nenci; G Goracci
Journal:  Agents Actions       Date:  1990-03

3.  Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats.

Authors:  Carmelo Muià; Emanuela Mazzon; Daniele Zito; Daniele Maiere; Domenico Britti; Concetta Crisafulli; Giacomo Oteri; Giancarlo Cordasco; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-28       Impact factor: 3.000

4.  In vitro inhibition of human polymorphonuclear cell function by cloricromene.

Authors:  F Bertocchi; F Breviario; P Proserpio; J M Wang; P Ghezzi; R A Travagli; M Prosdocimi; E Dejana
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

5.  Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation.

Authors:  E Ribaldi; A M Mezzasoma; E Francescangeli; M Prosdocimi; G G Nenci; G Goracci; P Gresele
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

6.  Inhibition of human monocyte adhesion to endothelial cells by the coumarin derivative, cloricromene.

Authors:  S Tranchina; S Bernasconi; E Dejana; A Del Maschio
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.